RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients
PurposeMicroRNA-497 (miR-497) is previously reported to target fibroblast growth factor 23 (FGF-23) and regulates cardiac injury, while their value in predicting drug-induced cardiotoxicity is not reported. Thus, the current study aimed to investigate the correlation of miR-497/FGF-23 with neoadjuva...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Surgery |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fsurg.2022.862617/full |
| _version_ | 1797224717256491008 |
|---|---|
| author | Hui Liu Xiaoyan Hu Lingyun Wang Tao Du Jing Feng Ming Li Lei Liu Xiaofang Liu |
| author_facet | Hui Liu Xiaoyan Hu Lingyun Wang Tao Du Jing Feng Ming Li Lei Liu Xiaofang Liu |
| author_sort | Hui Liu |
| collection | DOAJ |
| description | PurposeMicroRNA-497 (miR-497) is previously reported to target fibroblast growth factor 23 (FGF-23) and regulates cardiac injury, while their value in predicting drug-induced cardiotoxicity is not reported. Thus, the current study aimed to investigate the correlation of miR-497/FGF-23 with neoadjuvant/adjuvant trastuzumab-induced cardiotoxicity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients.MethodsA total of 97 HER2-positive surgical breast cancer patients who received neoadjuvant/adjuvant trastuzumab contained regimens were enrolled; then, their peripheral blood mononuclear cells (PBMC) and serum were collected at baseline, after neoadjuvant treatment, at 3 months (M3), 6 months (M6), 9 months (M9), and 12 months (M12) after surgery. The PBMC was used for miR-497 measurements, and the serum was used for FGF-23 measurements. The cardiotoxicity events and incidence were recorded.ResultsA total of 24 (24.7%) patients occurred cardiotoxicity during the treatment period. MiR-497 decreased from baseline (median: 0.955) to M12 after surgery (median: 0.602) (p < 0.001), while FGF-23 increased from baseline (median: 0.390 ng/mL) to M12 after surgery (median: 0.566 ng/mL) (p < 0.001); besides, the miR-497/FGF-23 axis greatly reduced from baseline (median: 2.545) to M12 after surgery (median: 1.222) (p < 0.001). At most time points, miR-497 was negatively related to FGF-23 (all p < 0.05). Notably, the miR-497/FGF-23 axis at all time points (including baseline, postneoadjuvant treatment, M3, M6, M9, and M12) was related to a lower risk of cardiotoxicity (all p < 0.05). Furthermore, the miR-497/FGF-23 axis was also positively correlated with the left ventricular ejection fraction (LVEF) at all time points (all p < 0.01).ConclusionThe MiR-497/FGF-23 axis serves as a potential indicator predicting trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients. |
| first_indexed | 2024-03-11T18:57:14Z |
| format | Article |
| id | doaj.art-1aea3d2095084eeda5e32792490b64ed |
| institution | Directory Open Access Journal |
| issn | 2296-875X |
| language | English |
| last_indexed | 2024-04-24T13:57:33Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Surgery |
| spelling | doaj.art-1aea3d2095084eeda5e32792490b64ed2024-04-03T16:28:04ZengFrontiers Media S.A.Frontiers in Surgery2296-875X2022-05-01910.3389/fsurg.2022.862617862617RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer PatientsHui LiuXiaoyan HuLingyun WangTao DuJing FengMing LiLei LiuXiaofang LiuPurposeMicroRNA-497 (miR-497) is previously reported to target fibroblast growth factor 23 (FGF-23) and regulates cardiac injury, while their value in predicting drug-induced cardiotoxicity is not reported. Thus, the current study aimed to investigate the correlation of miR-497/FGF-23 with neoadjuvant/adjuvant trastuzumab-induced cardiotoxicity in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients.MethodsA total of 97 HER2-positive surgical breast cancer patients who received neoadjuvant/adjuvant trastuzumab contained regimens were enrolled; then, their peripheral blood mononuclear cells (PBMC) and serum were collected at baseline, after neoadjuvant treatment, at 3 months (M3), 6 months (M6), 9 months (M9), and 12 months (M12) after surgery. The PBMC was used for miR-497 measurements, and the serum was used for FGF-23 measurements. The cardiotoxicity events and incidence were recorded.ResultsA total of 24 (24.7%) patients occurred cardiotoxicity during the treatment period. MiR-497 decreased from baseline (median: 0.955) to M12 after surgery (median: 0.602) (p < 0.001), while FGF-23 increased from baseline (median: 0.390 ng/mL) to M12 after surgery (median: 0.566 ng/mL) (p < 0.001); besides, the miR-497/FGF-23 axis greatly reduced from baseline (median: 2.545) to M12 after surgery (median: 1.222) (p < 0.001). At most time points, miR-497 was negatively related to FGF-23 (all p < 0.05). Notably, the miR-497/FGF-23 axis at all time points (including baseline, postneoadjuvant treatment, M3, M6, M9, and M12) was related to a lower risk of cardiotoxicity (all p < 0.05). Furthermore, the miR-497/FGF-23 axis was also positively correlated with the left ventricular ejection fraction (LVEF) at all time points (all p < 0.01).ConclusionThe MiR-497/FGF-23 axis serves as a potential indicator predicting trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients.https://www.frontiersin.org/articles/10.3389/fsurg.2022.862617/fullmicroRNA-497fibroblast growth factor 23neoadjuvant/adjuvanttrastuzumab induced cardiotoxicityHER2-positive breast cancer |
| spellingShingle | Hui Liu Xiaoyan Hu Lingyun Wang Tao Du Jing Feng Ming Li Lei Liu Xiaofang Liu RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients Frontiers in Surgery microRNA-497 fibroblast growth factor 23 neoadjuvant/adjuvant trastuzumab induced cardiotoxicity HER2-positive breast cancer |
| title | RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients |
| title_full | RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients |
| title_fullStr | RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients |
| title_full_unstemmed | RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients |
| title_short | RETRACTED: Longitude Variation of the microRNA-497/FGF-23 Axis during Treatment and Its Linkage with Neoadjuvant/Adjuvant Trastuzumab-Induced Cardiotoxicity in HER2-Positive Breast Cancer Patients |
| title_sort | retracted longitude variation of the microrna 497 fgf 23 axis during treatment and its linkage with neoadjuvant adjuvant trastuzumab induced cardiotoxicity in her2 positive breast cancer patients |
| topic | microRNA-497 fibroblast growth factor 23 neoadjuvant/adjuvant trastuzumab induced cardiotoxicity HER2-positive breast cancer |
| url | https://www.frontiersin.org/articles/10.3389/fsurg.2022.862617/full |
| work_keys_str_mv | AT huiliu retractedlongitudevariationofthemicrorna497fgf23axisduringtreatmentanditslinkagewithneoadjuvantadjuvanttrastuzumabinducedcardiotoxicityinher2positivebreastcancerpatients AT xiaoyanhu retractedlongitudevariationofthemicrorna497fgf23axisduringtreatmentanditslinkagewithneoadjuvantadjuvanttrastuzumabinducedcardiotoxicityinher2positivebreastcancerpatients AT lingyunwang retractedlongitudevariationofthemicrorna497fgf23axisduringtreatmentanditslinkagewithneoadjuvantadjuvanttrastuzumabinducedcardiotoxicityinher2positivebreastcancerpatients AT taodu retractedlongitudevariationofthemicrorna497fgf23axisduringtreatmentanditslinkagewithneoadjuvantadjuvanttrastuzumabinducedcardiotoxicityinher2positivebreastcancerpatients AT jingfeng retractedlongitudevariationofthemicrorna497fgf23axisduringtreatmentanditslinkagewithneoadjuvantadjuvanttrastuzumabinducedcardiotoxicityinher2positivebreastcancerpatients AT mingli retractedlongitudevariationofthemicrorna497fgf23axisduringtreatmentanditslinkagewithneoadjuvantadjuvanttrastuzumabinducedcardiotoxicityinher2positivebreastcancerpatients AT leiliu retractedlongitudevariationofthemicrorna497fgf23axisduringtreatmentanditslinkagewithneoadjuvantadjuvanttrastuzumabinducedcardiotoxicityinher2positivebreastcancerpatients AT xiaofangliu retractedlongitudevariationofthemicrorna497fgf23axisduringtreatmentanditslinkagewithneoadjuvantadjuvanttrastuzumabinducedcardiotoxicityinher2positivebreastcancerpatients |